BETA - How do t-cells develop and change? (2026 Update)

BETA - How do t-cells develop and change? (2026 Update)
Myeloma Treatment Debates: Key CoMy 2026 Controversies and Clinical Decisions with Mohamad Mohty
DREAMM-9 Final Analysis: Blenrep + VRd Shows Lasting Benefit in Newly Diagnosed Myeloma | EHA 2026
Beyond One-Size-Fits-All: Martin Kaiser on Precision Diagnostics in Multiple Myeloma | EHA 2026
Beyond IMiDs: Cemsidomide — A Next-Generation Cereblon Degrader Shows Promise in Myeloma | EHA 2026
Talquetamab Steps Forward: MonumenTAL-3 - A New Potential for GPRC5D Therapy in Myeloma | EHA 2026
CAR-T Without the Wait: Reprogramming T-cells Inside Your Body for Myeloma | EHA 2026
Next Generation of CAR-T: AZD0120 Dual BCMA/CD19 CAR-T w/ Rapid Manufacturing for Myeloma | EHA 2026
Next Generation of CAR-T: AZD0120 Dual BCMA/CD19 CAR-T w/ Rapid Manufacturing for Myeloma | EHA 2026
Beyond MRD Negative: FORTE Trial Reveals Why Staying MRD Negative Matters in Myeloma | ASCO 2026
Duffy Null & High-Risk Myeloma in Black Patients: Insights from CoMMpass & HORIZON Study | EHA 2026
Is Autologous Stem Cell Transplant Still Standard of Care in Myeloma? New Data from EHA 2026
Arlocabtagene Autoleucel (Arlo-Cel): Promising GPRC5D CAR-T Results in Relapsed Myeloma | EHA 2026
CAR-T vs Bispecifics — Which Performs Better in Myeloma After Initial BCMA Therapy Fails? | #EHA2026
A New Way to Deliver Isatuximab in Myeloma: Safety Insights on the On-Body Injector (OBI) | #EHA2026